Evaluating PET/CT for SSTR-related diseases
Somatostatin Receptor PET/CT in SSTR-Related Disease Patients
This study is testing a new type of PET/CT scan to see if it can help find cancer spots in adults who have tumors related to SSTR diseases.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Tianjin Medical University Academic / other |
| Locations | 1 site (Tianjin, Tianjin Municipality) |
| Trial ID | NCT06690957 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of 68Ga/18F-TATE/JR11/LM3 positron emission tomography/computed tomography (PET/CT) in diagnosing primary and metastatic lesions in patients with SSTR-related diseases. Participants, who are adults with suspected or diagnosed malignant tumors, undergo PET/CT scans to assess the uptake of the imaging agent in their lesions. The study aims to calculate various diagnostic metrics, including sensitivity and specificity, to determine the accuracy of this imaging technique in clinical settings.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with suspected or diagnosed malignant tumors requiring SSTR PET/CT scans.
Not a fit: Patients with non-malignant lesions or those unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the diagnostic accuracy for patients with SSTR-related diseases, leading to better treatment planning.
How similar studies have performed: While similar imaging techniques have been explored, this specific approach using 68Ga/18F-TATE/JR11/LM3 PET/CT is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled SSTR PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: \- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Where this trial is running
Tianjin, Tianjin Municipality
- Tianjin Medical University General Hospital — Tianjin, Tianjin Municipality, China (Recruiting)
Study contacts
- Study coordinator: Haonan Yu, MD
- Email: dreamadam@126.com
- Phone: +8613821000597
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.